ESTRO 2023 - Abstract Book

S1058

Digital Posters

ESTRO 2023

Conclusion 22% of patients that have undergone lung SBRT treatments in our institution developed pain or CW injury. Although high doses, aged patients and presence of osteoporosis seem to work in favour of CW toxicity, no apparent correlation has been found in our study.

Structured information might be the standard way of reporting for efficient data mining.

Further studies may include a radiomic analysis to evaluate bone density and its clinical relevance with rib failure.

PO-1321 Prophylactic cranial irradiation in small cell lung cancer: a re-evaluation of the current evidence

Abstract withdrawn

PO-1322 Early cardiac toxicity in stage III non-small cell lung cancer: preliminary dosimetric analysis

M. Miele 1 , E. Ippolito 2 , M. Fiore 3 , C. Greco 3 , M. Benincasa 4 , M. Carpenito 5 , S. Mega 5 , F. Grigioni 6 , S. Ramella 3

1 Operative Research Unit of Radiation Oncology, Campus Bio-Medico University Hospital Foundation, Unit Of Radiation Oncology, Rome, Italy; 2 Research Unit of Radiation Oncology, Department of Medicine and Surgery, University of Campus Bio-Medico of Rome, Unit of Radiation Oncology,, Rome, Italy; 3 Research Unit of Radiation Oncology, Department of Medicine and Surgery, University of Campus Bio-Medico of Rome, Unit of Radiation Oncology, Rome, Italy; 4 Operative Research Unit of Radiation Oncology, University of Campus Bio-Medico of Rome, Unit of Radiation Oncology, Rome, Italy; 5 Operative Research Unit of Cardiology, University of Campus Bio-Medico of Rome, Unit of Cardiology, Rome, Italy; 6 Research Unit of Cardiology Department of Medicine and Surgery, University of Campus Bio-Medico of Rome, Unit of Cardiology, Rome, Italy Purpose or Objective The aim of this study was to prospectively investigate a correlation between the heart dosimetry and early heart damage in patients with locally advanced non small cell lung cancer (LA-NSCLC) undergoing chemoradiotherapy (CRT). Materials and Methods This trial is a prospective, observational cohort study including patients with stage IIIA-IIIB NSCLC who underwent concomitant chemoradiotherapy (CRT). Radiotherapy was delivered with a median total dose of 60 Gy with conventional fractionation. The 3D techinique or Intesity-modulated radiotherapy (IMRT) was used. Manual contouring of target and organs at risk (OAR) was performed from the simulation CT images. The difference in cardiac dosimetry in patients who have experienced cardiac and no-cardiac events (CV) was assessed by T-Test. Subsequently, dosimetric parameters that resulted different between patients who experienced CV and patients who did not, were subjected to regression analysis. Results This preliminary analysis included thirty-four patients with stage IIIA-IIIB NSCLC. The median age was 69.5 years (range, 43 87). The median follow-up was 27.8 months. 62% of patients were in stage IIIA. All patients were treated with concurrent CRT and in 65% of cases a platinum-based regimen was used. No patients died of CV complications. Eight patients (23.5%)